Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Dual-targeting of B & T Cell Pathways Evaluation Trial (DUET)

12. listopadu 2026 aktualizováno: Diabetes Free, Inc.

Evaluation of Safety, Treatment Response and Biological Effects of DFI205 in Systemic Autoimmune Rheumatic Diseases (SARDs); a Phase 1/2a First-in-Human (FIH) Study

This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

72

Fáze

  • Fáze 2
  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Male and female participants, age 18 years and older.
  • Able to understand and comply with all scheduled visits, treatment plans, laboratory tests, and other procedures of the study protocol including ability to provide written informed consent.
  • Maintaining a stable, qualifying, standard of care regimen for ≥4 weeks prior to screening as treatment for a qualifying primary diagnosis (RA, SLE, SSc, IIM including the disease-specific criteria listed below):
  • Rheumatoid Arthritis (RA) participants must have, 1) positivity of anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF); 2) moderate to highly active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months; secondary Sjögren's disease diagnosis is acceptable as long as other criteria are met.
  • Systemic Lupus Erythematosus (SLE) participants must have, 1) positivity of anti-nuclear-antibodies (ANA) and/or anti-dsDNA and/or anti-histone and/or anti-nucleosome and/or anti-Sm antibodies; 2) active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months.
  • Systemic Sclerosis (SSc) participants must have, 1) positivity for at least one SSc-associated autoantibody; 2) mRSS score >10 units or interstitial lung disease (ILD) including clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≤ 5 years (from onset of first non-Raynaud manifestation); 4) not eligible for or declining autologous hematopoietic stem-cell transplantation
  • Idiopathic Inflammatory Myopathies (IIM) participants must have, 1) positivity for at least one myositis-specific antibody; 2) active myositis or presence of ILD defined by clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months

Exclusion Criteria:

  • Diagnosis of a non-rheumatic autoimmune disease requiring therapeutic or investigational immune therapy or modulation (e.g., neuropathy requiring IVIg, Multiple Sclerosis). Milder autoimmune conditions requiring replacement or exocrine functional therapies are acceptable (e.g., Type 1 diabetes, Celiac Disease, Autoimmune Thyroid Disease if on stable treatment for at least 6 months).
  • History of any pre-existing liver disease, including cirrhosis, acute liver disease, or chronic liver disease (unless considered stable for >6 months and required screening laboratory tests meet criteria).
  • Severe unresolved cardiac disease.
  • Estimated glomerular filtration rate (GFR) <30 mL/min/1.73 m2.
  • Presence or history of active infections, including hepatitis B, hepatitis C, human immunodeficiency virus (HIV), Human T-lymphotropic virus (HTLV) or tuberculosis. Participants with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection. Participants with mild skin and nail fungal infections are not excluded.
  • Acute infection requiring systemic therapy or hospitalization within 30 days before screening.
  • Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to enrollment.
  • Any history of malignancy in the 5 years before screening except for completely resected squamous or basal cell carcinoma of the skin.
  • Primary or secondary immunodeficiency, including hypogammaglobulinemia.
  • History or evidence of progressive multifocal leukoencephalopathy (PML) or other demyelinating disorders.
  • Allergies to humanized monoclonal antibodies or severe post-treatment hypersensitivity reactions other than localized injection site reaction, to any biological molecule.
  • Systemic corticosteroid therapy or adrenocorticotropic hormone (ACTH) use within 30 days prior to screening and within entire duration of screening period prior to beginning of study treatment, unless prescribed as background therapy.
  • Intolerance of or contraindication to oral or IV corticosteroids.
  • Treatment with other biologic or non-biologic immunosuppressant agents (e.g., anti-CD20 therapies, TNF inhibitors, azathioprine, cyclosporine, methotrexate, or mycophenolate) within 6 months prior to screening, unless prescribed as background therapy.
  • The participant has taken another investigational drug within 3 months or 5-half-lives before the screening visit, whichever is longer, or any investigational drug that has depleted a cell type or line without recovery.
  • Previous treatment with anti-CD19 agents, anti-CD38 agents, bispecific anti-CD19/CD3 T cell engaging therapies, adoptive T cell therapy or any prior gene therapy product.
  • Received any form of stem cell transplant.
  • Administration of live attenuated vaccine(s) within 12 weeks prior to and 12 weeks after the completion of DFI205 administration or any planned receipt during the study that cannot be delayed. Vaccinations should be up-to-date as per local clinical practice.
  • Plasmapheresis within 3 months prior to first dose of DFI205
  • Positive pregnancy test, presently breast-feeding, (female participants) or unwillingness to use highly effective contraceptive measures for the duration of the study and 6 months after discontinuation.
  • Any condition, including the presence of relevant abnormalities in vital parameters or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Phase 1 Single Ascending Dose Escalation

Intravenous (IV) infusion of DFI205 at ascending dose levels.

A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.

Experimentální: Phase 2a Multi-Dose

DFI205 monthly IV infusions at the recommended Phase 2 dose

A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
To evaluate the initial safety and tolerability of DFI205 in adults with SARDs
Časové okno: Up to 1 year post-dosing

Numbers and types of all adverse events (AEs) and serious adverse events (SAEs)

Up to 1 year post-dosing
To monitor immune reconstitution after completion of dosing with DFI205
Časové okno: Up to 1 year post-dosing

Time to normalized peripheral blood B cell counts compared to baseline.

Up to 1 year post-dosing
To monitor immune response to DFI205
Časové okno: Up to 1 year post-dosing

Number of participants with anti-drug antibody development.

Up to 1 year post-dosing

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
To evaluate the ability of DFI205 to induce an objective response in adults with RA
Časové okno: 24 weeks post-dosing

Overall Response Rate (ORR) measured by proportion of participants achieving either low-disease activity (DAS28-CRP ≤ 3.2, DAS28-ESR ≤3.2, SDAI≤11, CDAI≤10) or remission criteria (DAS28-CRP < 2.6, DAS28-ESR <2.6, SDAI ≤3.3, CDAI ≤ 2.8,Boolean 2.0 remission criteria) combined

24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with SLE
Časové okno: 24 weeks post-dosing

Overall Response Rate (ORR) measured by fulfillment of DORIS remission criteria

24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with SSc
Časové okno: 24 weeks post-dosing

Overall Response Rate (ORR) measured by proportion of participants achieving either modified Rodnan Skin Score (mRSS) decrease of >5 points and ≥ 25% decrease from baseline or no progression of interstitial lung disease (ILD progression defined as FVC decline >10%, or 5-10% plus worsening respiratory symptoms or HRCT progression) combined

24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with IIM
Časové okno: 24 weeks post-dosing

Overall Response Rate (ORR) measured by achievement of major response (ACR/EULAR 2016 Myositis Response Criteria Total Improvement Score ≥ 60)

24 weeks post-dosing

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Časové okno: 24 weeks post-dosing

Change in tender joint count (TJC28) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Časové okno: 24 weeks post-dosing

Change in swollen joint count (SJC28) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with SLE
Časové okno: 24 weeks post-dosing

Change in British Isles Lupus Assessment Group (BILAG-2004) score compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with SSc
Časové okno: 24 weeks post-dosing

Change in mRSS (0=no thickening, 3=severe thickening) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Časové okno: 24 weeks post-dosing

Change in creatine phosphokinase (CPK) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Časové okno: 24 weeks post-dosing

Change in muscle strength (MMT8 score) compared to baseline

24 weeks post-dosing
To evaluate change in erythrocyte sedimentation rate (ESR) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Časové okno: Up to 1 year post-dosing
Up to 1 year post-dosing
To evaluate change in C-reactive protein (CRP) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Časové okno: Up to 1 year post-dosing
Up to 1 year post-dosing
To evaluate change in interleukin-6 (IL-6) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Časové okno: Up to 1 year post-dosing
Up to 1 year post-dosing
To evaluate change in tumor necrosis factor-alpha (TNF-α) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Časové okno: Up to 1 year post-dosing
Up to 1 year post-dosing
To investigate the pharmacokinetics of DFI205
Časové okno: Up to 1 year post-dosing

Blood samples will be collected to quantitate serum concentrations of DFI205

Up to 1 year post-dosing
To investigate the pharmacodynamics of DFI205 in blood
Časové okno: Up to 1 year post-dosing

Proportions of immune cell subsets in blood by FACS analysis over the course of the study.

Up to 1 year post-dosing
To investigate the secondary lymphoid system pharmacodynamics of DFI205
Časové okno: Up to 1 year post-dosing

Proportions of disease-specific lymph node cell populations over the course of the study.

Up to 1 year post-dosing
To investigate soluble CD40 pharmacodynamics of DFI205
Časové okno: Up to 1 year post-dosing

Soluble CD40 receptor/ligand blood concentrations over the course of the study treatments.

Up to 1 year post-dosing

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Georg Schett, M.D., University of Erlangen-Nürnberg

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. prosince 2026

Primární dokončení (Odhadovaný)

1. srpna 2028

Dokončení studie (Odhadovaný)

1. prosince 2028

Termíny zápisu do studia

První předloženo

3. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

12. listopadu 2026

První zveřejněno (Aktuální)

18. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 2026TXSARD01
  • 2026-526672-24-00 (Ctis)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .